ArticleCureus2026
Primary Leiomyosarcoma of the Breast in a Patient With a History of Phyllodes Tumor.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary breast leiomyosarcoma is a rare mesenchymal malignancy, thought to arise from smooth muscle elements of the nipple-areolar complex, vascular structures, or stromal tissue. Owing to its low incidence, current knowledge is largely derived from isolated case reports and small case series. Patients typically present with a painless, gradually enlarging breast mass, while imaging findings are often non-specific, posing diagnostic challenges. Definitive diagnosis relies on histopathological evaluation supplemented by immunohistochemistry (IHC) to differentiate it from other spindle cell neoplasms of the breast. Treatment strategies are extrapolated from the management of soft-tissue sarcomas at other sites, with wide local excision and negative surgical margins forming the mainstay of therapy. The role of adjuvant radiotherapy and chemotherapy remains unclear due to limited evidence and a lack of consensus guidelines. Given its rarity, reporting such cases is essential to enhance understanding of its clinical behavior, optimize management approaches, and inform future therapeutic recommendations. A patient in her 30s, status post a simple mastectomy two years ago (histopathological diagnosis: borderline malignant phyllodes tumor), presented with a rapidly growing right chest wall swelling. Ultrasound of the swelling showed an oval, well-circumscribed, heterogeneous lesion measuring 3.9 cm × 2.8 cm, with solid and cystic components in the right chest wall. Fine-needle aspiration showed clusters of spindle cells with nuclear atypia. Wide local excision demonstrated a high-grade spindle cell tumor, confirmed by histopathology and IHC (smooth muscle actin positive, Ki-67 >10%) as leiomyosarcoma. On follow-up, no evidence of residual disease or distant metastasis was identified. This case highlights the challenges in diagnosing rare breast sarcomas, the potential for recurrence or transformation of phyllodes tumors, and the reliance on complete surgical excision followed by adjuvant radiotherapy for optimal local disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.